Molecular structure of PSC 833, CAS Number: 121584-18-7
PSC 833 (CAS 121584-18-7)
See product citations (12)
Alternate Names:
Valspodar; 6-[(2S,4R,6E)-4-methyl-2-(methylamino)-3-oxo-6-octenoic acid]-7-L-valine-cyclosporin A
Application:
PSC 833 is a P-glycoprotein (P-gp, Mdr-1) modulator shown to inhibit P-gp-mediated multidrug-resistance (MDR).
CAS Number:
121584-18-7
Purity:
≥98%
Molecular Weight:
1214.62
Molecular Formula:
C63H111N11O12
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
PSC 833 is a potent inhibitor of P-glycoprotein, a membrane protein that functions as an efflux pump. PSC 833 is used to study the role of P-glycoprotein in resistance and to investigate potential strategies to overcome this resistance. PSC 833 is a substrate for P-glycoprotein and competes for binding to the protein, effectively blocking its ability to pump out of the cell.
PSC 833 (CAS 121584-18-7) References
- Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. | Song, S., et al. 1999. Drug Metab Dispos. 27: 689-94. PMID: 10348798
- 99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours. | Bakker, M., et al. 1999. Anticancer Res. 19: 2349-53. PMID: 10472354
- SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein. | Goulding, CW., et al. 2000. Cancer Lett. 149: 143-51. PMID: 10737718
- Effect of PSC 833 on the cytotoxicity and pharmacodynamics of mitoxantrone in multidrug-resistant K562 cells. | Fukushima, T., et al. 2000. Leuk Res. 24: 249-54. PMID: 10739007
- Effect of PSC 833 liposomes and Intralipid on the transport of epirubicin in Caco-2 cells and rat intestines. | Lo, Y., et al. 2001. J Control Release. 76: 1-10. PMID: 11532308
- Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma. | Cagliero, E., et al. 2004. Oncol Rep. 12: 1023-31. PMID: 15492788
- PSC 833, an inhibitor of P-glycoprotein inhibits 1,2-dimethylhydrazine-induced colorectal carcinogenesis in male Fischer F344 rats. | Kankesan, J., et al. 2006. Anticancer Res. 26: 995-9. PMID: 16619498
- Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models. | Watanabe, T., et al. 1996. Jpn J Cancer Res. 87: 184-93. PMID: 8609068
- [SDZ PSC 833: a novel modulator of MDR]. | Covelli, A. 1997. Tumori. 83: S21-4. PMID: 9446255
- The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation. | Cabot, MC., et al. 1998. FEBS Lett. 431: 185-8. PMID: 9708899
- PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance. | Atadja, P., et al. 1998. Cancer Metastasis Rev. 17: 163-8. PMID: 9770112
- Dose-dependent effects of PSC 833 on its tissue distribution and on the biliary excretion of endogenous substrates in rats. | Song, S., et al. 1998. Drug Metab Dispos. 26: 1128-33. PMID: 9806956
- Modulation of the tumor disposition of vinca alkaloids by PSC 833 in vitro and in vivo. | Song, S., et al. 1998. J Pharmacol Exp Ther. 287: 963-8. PMID: 9864280
Inhibitor of:
ABC-me, ABCA16, ABCC11, ABCF3, Abcg3, GlnP, Mdr-1, OATP-B, OATP-I, PPIL2, and TAP2.Activator of:
MRP6.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PSC 833, 1 mg | sc-361298 | 1 mg | $213.00 | |||
PSC 833, 10 mg | sc-361298A | 10 mg | $724.00 | |||
PSC 833, 50 mg | sc-361298B | 50 mg | $2522.00 | |||
PSC 833, 100 mg | sc-361298C | 100 mg | $4253.00 | |||
PSC 833, 1 g | sc-361298D | 1 g | $26884.00 |